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Abstract
Background and Objective Tendon rupture can result from fluoroquinolone exposure. The objective of this study was to 
quantify relative and absolute risk and determine how risk is affected by timing of exposure.
Methods The UK Health Improvement Network primary care database was used to perform a nested case–control study 
measuring the association between fluoroquinolone exposure and tendon rupture. Adults with tendon rupture were matched 
on age, sex, general practice and calendar time to four controls selected from a cohort prescribed systemic fluoroquinolone 
or co-amoxiclav antibiotics. The relative and absolute risk of tendon rupture with fluoroquinolone exposure was calculated.
Results Current fluoroquinolone exposure was associated with an increased risk of any tendon rupture (adjusted incidence 
rate ratio [aIRR] 1.61, 95% CI 1.25–2.09) and Achilles tendon rupture (aIRR 3.14, 95% CI 2.11–4.65) that persisted for 
60 days. Risk increased with cumulative exposure and was greatest when co-prescribed with oral corticosteroids (aIRR 19.36, 
95% CI 7.78–48.19 for Achilles tendon rupture). The adjusted rate difference (aRD) with fluoroquinolone exposure was 2.9 
and 2.1 per 10,000 patients for any and Achilles tendon rupture, respectively, and was greatest in people aged ≥ 60 years 
prescribed concomitant oral corticosteroid therapy (aDR 19.6 for any tendon and 6.6 Achilles tendon rupture per 10,000). 
No association was seen with co-amoxiclav or statin exposure, or with biceps or other tendon ruptures.
Conclusions Risk of tendon rupture with fluoroquinolones depends on timing, cumulative dose and concomitant exposure 
to oral corticosteroids. Absolute risk significantly varied by age and concomitant corticosteroid exposure, affecting elderly 
patients the greatest.
Key Points 
Risk of tendon rupture with fluoroquinolones depends 
upon timing, cumulative dose and concomitant exposure 
to oral corticosteroids.
Absolute risk varied by age and concomitant corticoster-
oid exposure, affecting elderly patients the greatest.
1 Introduction
Fluoroquinolone antibiotics are widely used to treat a broad 
range of infections, including those of the urinary respiratory 
and gastrointestinal systems, with variation in the prevalence 
of prescribing and indications for use within different health 
systems [1]. However, fluoroquinolones cause important side 
effects as listed in their Summary of Product Characteristics 
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(SPC), which include tendon ruptures that are listed as 
occurring very rarely with a frequency of less than 1 per 
10,000 patients [2, 3]. Tendon ruptures manifest as complete 
or partial rupture of the tendon and are an important cause 
of morbidity, affecting both functional ability and quality of 
life with treatment often involving invasive surgery [4, 5]. 
The incidence of tendon rupture in the general population 
varies according to tendon site, with estimates ranging from 
4.7 to 55.2 per 100,000 person-years for Achilles tendon 
rupture, and 2.6 to 5.4 per 100,000 person-years for biceps 
tendon rupture [6–8]. The mechanism for fluoroquinolone-
induced tendon rupture remains uncertain, but has been 
linked to changes in collagen fibrils following alterations in 
the regulation of matric metalloproteinases associated with 
non-traumatic rupture [9]. Although some risk factors for 
tendon rupture have been identified such as increasing age, 
male gender, obesity, diabetes, corticosteroid therapy and 
recreational sports [10–12], a further understanding of risk 
factors is needed to identify at-risk individuals and minimize 
unintended harm.
In 1995, the US Food and Drug Administration (FDA) 
updated fluoroquinolone product labelling with a warning 
about the possibility of tendon rupture, followed by a ‘black 
box’ warning in 2008 [13]. In May 2016, the FDA conducted 
a review of disabling and potentially irreversible serious side 
effects of fluoroquinolones resulting in a restriction of their 
use in less severe infections of acute sinusitis, acute bron-
chitis and uncomplicated urinary tract infections when other 
treatment options are available [14]. The European Medi-
cines Agency (EMA) Pharmacovigilance Risk Assessment 
Committee (PRAC) has also recently reviewed the persis-
tence of fluoroquinolones adverse reactions to help deter-
mine the need for any restriction in indication, and required 
further data to characterise the risk of such reactions [15]. 
Whilst the risk of tendon rupture is recognized, there is 
inconsistency in its reported size with relative risk rang-
ing between 1.9- and 5.3-fold increased risk, with limited 
information on absolute risk [10, 16–21]. The aim of this 
study was to quantify the relative and absolute risk of tendon 
rupture with fluoroquinolone exposure, and to investigate 
factors influencing this risk.
2  Methods
2.1  Data Source
The THIN database contains electronic patient records 
extracted from > 500 general practices across the UK cov-
ering approximately 6% of the UK population. Data are rep-
resentative of the UK population in terms of age, gender, 
deprivation status and geographical distribution [22]. Data 
are linked via an anonymous ID number allowing patients to 
be followed longitudinally over time. THIN contains diag-
nostic, prescription and lifestyle information. Diagnoses, 
symptoms, procedures and other relevant health information 
are coded using the Read Code clinical classification system. 
The Read Code system has been the standard approach to 
recording patient data in UK primary care since 1990, and 
is a hierarchical classification system, linked to the Inter-
national Classification of Diseases [23]. Data quality con-
trol measures available in THIN include The Acceptable 
Mortality Reporting (AMR) data specific to each practice 
and defines the date from which computerised recording of 
mortality data has reached an acceptable standard [24].
2.2  Study Population
The study population consisted of adults ≥ 18 years of age 
identified in THIN between 1 January 1999 and 31 Decem-
ber 2015 who were issued at least one prescription of co-
amoxiclav or fluoroquinolone antibiotic with a systemic 
route of administration. Co-amoxiclav was chosen so that 
controls were sampled from a more representative popula-
tion prescribed antibiotics to circumvent problems related 
to confounding by indication and by severity. Cohort entry 
was defined as the date of the first co-amoxiclav or fluoro-
quinolone prescription for systemic administration after the 
latest of the following criteria: start of the study period (1 
January 1999); the practice’s AMR date; the patient’s 18th 
birthday; date of registration with a general practice + 1 year. 
In this regard, all participants were required to have at least 
1 year of observation prior to cohort entry. Cohort exit was 
defined by the earliest of the following criteria: occurrence 
of the outcome; deregistration from the general practice; 
death; date of last data collection from the general practice; 
end of the study period (31 December 2015).
2.3  Study Design and Outcomes
A nested case–control study was used to efficiently account 
for time-varying confounders and time-varying exposure to 
prescribed medicines [25]. The date of the first event occur-
ring after cohort entry was the index date for case subjects. 
Tendon ruptures were first evaluated as any tendon ruptures 
and were then grouped according to their incidence: Achilles 
tendon; biceps tendon; and other tendon ruptures (consisting 
of triceps, hand/wrist, hamstrings/quadriceps, foot, shoul-
der, and non-specifically coded tendon ruptures) (see Online 
Supplementary Table S1)
2.4  Control Selection
Up to four controls were randomly selected and matched to 
each case on age decile, gender, general practice and calen-
dar year of cohort entry using incidence density sampling 
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[25]. The risk-set date for controls was the index date for 
cases. With incidence density sampling, ‘controls’ are a 
selection of person-moments from individuals who have not 
experienced the event at the index date. In this regard, con-
trols may be selected more than once, and people who sub-
sequently become cases may be selected as controls at earlier 
time points. Eighty-two cases of tendon rupture (1.7%) were 
unmatched to controls following the first round of matching 
criteria, and were subsequently included matched on age 
decile, gender and calendar year of cohort entry only, with 
sensitivity analyses conducted excluding these risk sets from 
the analysis.
2.5  Exposures
Systemic fluoroquinolone (ciprofloxacin, moxifloxacin, 
levofloxacin, norfloxacin and ofloxacin) and co-amoxiclav 
antibiotic exposure was measured by identifying prescrip-
tions issued within a pre-specified risk window prior to the 
index date. Fluoroquinolone and co-amoxiclav exposure was 
primarily defined as current exposure when one or more 
prescriptions were issued in a 30-day exposure risk window 
prior to the index date. Exposure risk windows 31–60 days, 
61–90 days and 91–180 days prior to the index date were 
then examined for systemic fluoroquinolone exposure to 
assess past exposure. Cumulative fluoroquinolone and co-
amoxiclav exposure was measured as the total number of 
days of systemic fluoroquinolone or systemic co-amoxiclav 
exposure prescribed within each risk window. Cumulative 
days exposure was calculated by dividing the prescription 
quantity information by the standard administration sched-
ule for each type of antibiotic as follows: oral co-amoxiclav 
three times a days; oral levofloxacin, moxifloxacin and nor-
floxacin once a day; ciprofloxacin and ofloxacin twice a day 
[26]. Prescriptions for oral suspension formulations were 
similarly calculated taking into account quantity information 
recorded in millilitres. Cumulative exposure was examined 
as a continuous variable predicting the increased risk asso-
ciated with each additional day of therapy during the risk 
window and also modelled with a categorical variable using 
the median days of exposure and interquartile range.
2.6  Confounders
Analyses were adjusted for exact age, sex and practice-level 
socioeconomic deprivation (inherent in the matching crite-
ria), smoking status, body mass index (BMI), exposure to 
oral and injectable corticosteroid therapy and statin therapy 
(defined as prescriptions issued within 90 days of the index 
date), and prior history of tendon rupture. Co-morbidity 
was accounted by adjusting for a history of hypothyroidism, 
hyperparathyroidism and the Charlson co-morbidity index, 
and then by modelling individual conditions in the Charlson 
co-morbidity index as a sensitivity analysis. The Charlson 
co-morbidity index is defined using the following clinical 
conditions: myocardial infarction, congestive heart failure, 
peripheral vascular disease, dementia, cerebrovascular dis-
ease, chronic lung disease, connective tissue disease, peptic 
ulcer, chronic liver disease, diabetes, hemiplegia, moderate 
or severe kidney disease, diabetes with complications, liver 
disease, cancer, cancer with metastasis and AIDS [27].
2.7  Data Analysis
Conditional logistic regression was used to calculate odds 
ratios for the association between tendon rupture and fluo-
roquinolone exposure and co-amoxiclav exposure. Using an 
incidence density sampling approach, odds ratios calculated 
in this way are estimators of incidence rate ratios (IRRs). 
Interaction between fluoroquinolone exposure and oral cor-
ticosteroid exposure was tested on the multiplicative scale. 
This was not done for statins as there was no statistically 
significant independent association with exposure. Adjusted 
rate differences (per 10,000 per year) were calculated for 
significant associations providing an absolute measure of 
effect [28]. Risk of exposure was presented for any tendon 
rupture and by type of tendon rupture.
Multiple imputation was used to impute missing data on 
body mass index (9.5% missing) and smoking status (2.1% 
missing). The imputation model included all variables relat-
ing to clinical characteristics, outcomes, medications, and 
fluoroquinolone and co-amoxiclav exposure. Multiple impu-
tation used fully conditional specification, with linear regres-
sion for continuous variables (BMI) and logistic regression 
for categorical variables (smoking status) with five impu-
tations and analysed using Rubin’s rules [29]. Sensitivity 
analyses were conducted varying the exposure risk window 
duration to 60 and 90 days, modelling individual Charlson 
co-morbidities, excluding traumatic tendon ruptures, exclud-
ing people with prior history of tendon rupture, and under-
taking a complete case analysis. Analysis was carried out 
using SAS Enterprise Guidev7.1 and STATAv15. The study 
was approved by the THIN Scientific Review Committee 
(17THIN087).
3  Results
The cohort contained 1,351,780 adult patients prescribed 
≥ 1 prescription for fluoroquinolone (34.3%) or co-amox-
iclav (65.7%) antibiotics (mean age of cohort 52.8 years, 
57.0% female). Overall, 4836 tendon rupture events were 
identified during cohort follow-up (incidence of any ten-
don rupture 5.9 per 10,000 person-years (pyrs) and of 
Achilles tendon rupture 1.9 per 10,000 pyrs) that were 
matched to 18,356 controls (Table 1). Cases and controls 
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were well matched on age, sex and duration of follow-up. 
The most common types of tendon rupture were: Achil-
les tendon (32.4%), biceps tendon (27.5%), shoulder 
tendons (16.6%), hand/wrist tendons (7.4%), hamstring/
quadriceps/patellar tendons (7.0%), foot/ankle tendons 
(0.8%) and triceps tendon (0.5%). Unspecified tendon 
ruptures accounted for 8.3% of all cases. The mean dura-
tion of cumulative fluoroquinolone exposure was 10.6 days 
(standard deviation, SD 8.9 days) and for co-amoxiclav 
was 8.6 days (SD 7.4 days).
3.1  Risk of Tendon Rupture with Fluoroquinolone 
Exposure
The relative incidence of any tendon rupture was signifi-
cantly elevated with current systemic fluoroquinolone expo-
sure (adjusted IRR [aIRR] 1.61, 95% CI 1.25–2.09). When 
stratified by type of tendon rupture, current fluoroquinolone 
exposure was associated with a significantly elevated rate of 
Achilles tendon rupture (aIRR 3.14, 95% CI 2.11–4.65) but 
not biceps tendon rupture (aIRR 1.07, 95% CI 0.61–1.89) 
or other tendon ruptures (aIRR 0.82, 95% CI 0.50–1.35) 
(Table 2). In contrast, the relative incidence of tendon rup-
tures was not significantly elevated with current co-amoxi-
clav exposure (Table 2).
Increasing cumulative days of systemic fluoroquinolone 
exposure was significantly associated with increased risk 
of Achilles tendon rupture (IRR 1.06, 95% CI 1.03–1.09). 
In contrast, no significant association was observed with 
cumulative co-amoxiclav exposure (Online Supplemen-
tary Table S2). The relative incidence of Achilles tendon 
rupture was significantly increased with systemic fluoro-
quinolone exposure within 1–30 days (aIRR 2.97, 95% CI 
1.98–4.43) and 31–60 days (aIRR 2.11, 95% CI 1.30–3.41) 
of the index date but not with systemic fluoroquinolone 
exposure occurring further in the past (aIRR 0.69, 95% CI 
0.41–1.16 for 61–90 days and aIRR 1.23, 95% CI 0.88–1.71 
for 91–180 days prior to the index date).
3.2  Relationship with Other Risk Factors
The adjusted relative incidence of tendon rupture was sig-
nificantly elevated in people with a history of prior tendon 
rupture, in those with oral corticosteroid therapy, and with 
Table 1  Characteristics of matched cases and controls
a At least one prescription within 90 days of the index date. Current 
fluoroquinolone exposure = prescription within 30  days of the index 
date
Characteristic Cases Controls
Number of individuals 4836 18,356
Female sex, no. (%) 1876 (38.8) 7164 (39.0)
Age (years), mean ± SD 61.6 (15.5) 61.3 (15.3)
Years of follow-up, mean ± SD 5.0 (3.7) 5.0 (3.7)
Body mass index, mean ± SD 28.1 (5.9) 27.7 (5.7)
Charlson co-morbidity index, mean ± SD 1.32 (1.61) 1.27 (1.64)
Hypothyroidism, no. (%) 365 (7.6) 1296 (7.1)
Hyperparathyroidism, no. (%) 17 (0.3) 61 (0.3)
Current smokers, no. (%) 765 (16.1) 3371 (18.8)
Oral corticosteroid therapy,a no. (%) 522 (10.8) 911 (5.0)
Injectable corticosteroid therapy,a no. (%) 43 (0.9) 32 (0.2)
Statin therapy,a no. (%) 326 (20.7) 1240 (20.6)
Current fluoroquinolone exposure, no. (%) 111 (2.3) 236 (1.3)
Current co-amoxiclav exposure, no. (%) 98 (2.0) 314 (1.7)
Prior history of tendon rupture, no. (%) 133 (2.8) 114 (0.6)
Table 2  Incidence rate ratios for the association between tendon rupture and current systemic fluoroquinolone and co-amoxiclav exposure
Model adjusted for exact age, body mass index, Charlson co-morbidity score, hypothyroidism, hyperparathyroidism, smoking status, oral and 
injectable corticosteroid therapy, statin therapy and prior history of tendon rupture
IRR incidence rate ratio
Tendon rupture Exposed cases/total Exposed controls/total Crude IRR Adjusted IRR Adjusted p value
Any tendon rupture
Fluoroquinolones 111/4836 236/18,356 1.79 (1.41–2.27) 1.61 (1.25–2.09) < 0.001
Co-amoxiclav 98/4836 314/18,356 1.15 (0.90–1.45) 1.02 (0.79–1.31) 0.900
Achilles tendon rupture
Fluoroquinolones 67/1577 82/6007 3.50 (2.45–5.02) 3.14 (2.11–4.65) < 0.001
Co-amoxiclav 38/1577 114/6007 1.19 (0.81–1.77) 1.00 (0.64–1.57) 0.989
Biceps tendon rupture
Fluoroquinolones 20/1316 62/4946 1.19 (0.71–2.00) 1.07 (0.61–1.89) 0.804
Co-amoxiclav 23/1316 74/4946 1.16 (0.72–1.88) 1.01 (0.61–1.66) 0.978
Other tendon rupture
Fluoroquinolones 24/1943 92/7403 0.94 (0.59–1.50) 0.82 (0.50–1.35) 0.439
Co-amoxiclav 37/1943 126/7403 1.09 (0.75–1.60) 1.01 (0.68–1.50) 0.946
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increasing BMI (Table 3). The risk of tendon rupture was not 
significantly associated with statin therapy or co-morbidity 
score, whilst smoking was associated with a reduced rela-
tive incidence of tendon rupture. A large significant inter-
action was observed with concomitant systemic fluoroqui-
nolone and oral corticosteroid exposure (aIRR 6.88, 95% 
CI 3.94–12.03 and aIRR 19.36, 95% CI 7.78–48.19, for any 
tendon rupture and Achilles tendon rupture, respectively, 
Table 4).
3.3  Absolute Risk
Adjusted rate differences for any tendon rupture and Achil-
les tendon rupture are presented overall and for age and sex 
(Table 5). Fluoroquinolone exposure caused an estimated 
2.9 tendon ruptures and 2.1 Achilles tendon ruptures per 
10,000 patients per year and was greatest in patients aged 
60 years and over. Concomitant oral corticosteroid exposure 
had a large impact on absolute risk, with the highest rates of 
tendon rupture associated with concomitant fluoroquinolone 
and corticosteroid exposure in males and in patients aged 
60 years and over.
3.4  Sensitivity Analyses
The relative incidence was elevated using 60-day and 90-day 
risk windows but was smaller in size with increasing risk-
window duration, whilst the results of all other sensitivity 
analyse were similar to those in the main analysis (Online 
Supplementary Table S3).
4  Discussion
Fluoroquinolone exposure significantly increased the risk of 
tendon rupture, which appeared to last up to 60 days follow-
ing exposure for Achilles tendon rupture. Risk was also esti-
mated to increase by ~ 6% with each additional day exposed 
Table 3  Association with any tendon rupture and Achilles tendon rupture and other potentially confounding variables and co-morbidities
Variables included separately in the model without interactions
IRR incident rate ratio, COPD chronic obstructive pulmonary disease
Variable Any tendon rupture Achilles tendon rupture
Adjusted IRR Adjusted p value Adjusted IRR Adjusted p value
Prior tendon rupture 4.60 (3.51–6.04) < 0.001 7.48 (4.53–12.35) < 0.001
Oral corticosteroid 2.25 (1.99–2.54) < 0.001 3.60 (2.89–4.48) < 0.001
Injectable corticosteroid 5.47 (3.36–8.91) < 0.001 1.82 (0.40–8.29) 0.435
Fluoroquinolone 1.61 (1.25–2.09) < 0.001 3.14 (2.11–4.65) < 0.001
Co-amoxiclav 1.02 (0.79–1.31) 0.900 1.00 (0.64–1.57) 0.989
Body mass index 1.01 (1.01–1.02) < 0.001 1.01 (1.00–1.03) 0.008
Statin therapy 1.06 (0.98–1.16) 0.129 0.96 (0.81–1.14) 0.650
Hypothyroidism 1.03 (0.90–1.17) 0.693 0.91 (0.70–1.18) 0.469
Hyperthyroidism 0.89 (0.51–1.55) 0.676 1.08 (0.41–2.89) 0.873
Charlson co-morbidity 0.99 (0.97–1.01) 0.279 1.00 (0.96–1.05) 0.975
 Connective tissue disease 2.03 (1.66–2.49) < 0.001 1.02 (0.63–1.65) 0.942
 COPD 1.07 (0.99–1.17) 0.096 1.24 (1.08–1.44) 0.003
 Cancer 0.97 (0.88–1.06) 0.473 0.98 (0.81–1.19) 0.854
 Chronic kidney disease 0.96 (0.86–1.07) 0.452 1.02 (0.82–1.28) 0.865
 Dementia 0.47 (0.34–0.66) < 0.001 0.34 (0.14–0.79) < 0.001
 Diabetes mellitus 1.01 (0.91–1.11) 0.854 1.03 (0.85–1.25) 0.758
 Heart failure 0.85 (0.71–1.01) 0.062 0.87 (0.64–1.25) 0.459
 Liver disease 0.87 (0.56–1.34) 0.521 1.04 (0.49–2.23) 0.916
 Myocardial infarction 1.07 (0.92–1.23) 0.404 0.96 (0.71–1.30) 0.796
 Peptic ulcer disease 1.09 (0.94–1.27) 0.263 1.01 (0.76–1.36) 0.921
 Peripheral vascular disease 0.90 (0.65–1.25) 0.543 0.85 (0.46–1.57) 0.606
 Stroke 1.04 (0.90–1.21) 0.579 1.03 (0.75–1.41) 0.878
Smoking
 Ex-smoker 1.04 (0.96–1.12) 0.360 0.85 (0.74–0.98) 0.029
 Current smoker 0.85 (0.78–0.94) 0.001 0.72 (0.61–0.85) < 0.001
210 D. R. Morales et al.
to fluoroquinolones within the current risk window and was 
increased markedly with concomitant exposure to oral cor-
ticosteroids. In contrast, co-amoxiclav exposure, which was 
chosen as a negative control, was not associated with an 
increased relative risk of any tendon rupture. Absolute risk 
of tendon rupture from fluoroquinolone exposure was greater 
than currently highlighted by product information and varied 
markedly according to age and concomitant exposure to oral 
corticosteroids.
Observational studies have previously investigated the 
risk of tendon rupture with fluoroquinolones with results 
varying in the size and precision of estimates. One case–con-
trol study consisting of only 38 cases of Achilles tendon 
rupture reported a relative risk with current exposure to 
fluoroquinolone antibiotics of 1.9 (95% CI 1.3–2.6), whilst 
a larger case–control study from Italy reported an 30% 
increased risk of any tendon rupture and a larger but less 
precise risk of Achilles tendon rupture (OR 4.1, 95% CI 
1.8–9.6 for Achilles tendon rupture) [16, 18]. Meanwhile, 
a small cohort study from Denmark has reported an age-
standardized incidence ratio of Achilles tendon rupture of 
3.1 (95% CI 1.0–7.3) within 90 days of incident fluoroqui-
nolone exposure whilst a further case–control study reported 
a larger risk of Achilles tendon rupture (odds ratio (OR) 5.3, 
95% CI 1.8–15.2) [17, 19]. However, these studies did not 
include an antibiotic-treated comparator in their design to 
help assess the presence of residual confounding.
One case-crossover study, whereby the patient acts as 
their own control, reported a smaller association with Achil-
les tendon rupture (OR 2.0, 95% CI 1.2–3.3) and used a 
composite of nitrofurantoin, amoxicillin and trimethoprim 
exposure as a negative control with no significant associa-
tion being observed [10]. This comparator group consisted 
of medications weighted towards the treatment of milder 
urinary tract infections. In contrast, a cohort study from 
Canada reporting an increased risk of tendon rupture with 
fluoroquinolones did use an active comparator of amoxicillin 
exposure that was also significantly associated with tendon 
rupture, suggesting the presence of residual confounding can 
affect the validity and size of the relative risk [20]. We used 
co-amoxiclav as a negative control because in the UK co-
amoxiclav is a similar broader-spectrum antibiotic reserved 
for more severe types of infection and may be less subject 
to unmeasured confounding compared to amoxicillin, nitro-
furantoin and trimethoprim. Similar to fluoroquinolones, 
co-amoxiclav is also associated with an increased risk of 
Clostridium difficile infection, which has resulted in similar 
changes to UK antibiotic prescribing guidelines during the 
study period.
Our study extends knowledge by demonstrating that risk 
appears to be present up to 60 days following treatment 
Table 4  Incidence rate ratios for the interaction between tendon rupture and current systemic fluoroquinolone and oral corticosteroid exposure
Adjusted for exact age, body mass index, Charlson co-morbidity score, hypothyroidism, hyperthyroidism, injectable corticosteroid therapy, 
smoking status, statin therapy and prior history of tendon rupture
IRR incidence rate ratio
Tendon rupture Exposed cases/total Exposed controls/total Adjusted IRR Adjusted p value
Any tendon rupture
Oral corticosteroid alone 287/4836 443/18,356 2.58 (2.19–3.03) < 0.001
Oral corticosteroid plus fluoro-
quinolone exposure
36/4836 20/18,356 6.88 (3.93–12.03) < 0.001
Achilles tendon rupture
Oral corticosteroid alone 148/1557 180/6007 4.59 (3.43–6.14) < 0.001
Oral corticosteroid plus fluoro-
quinolone exposure
37/1557 10/6007 19.36 (7.78–48.19) < 0.001
Table 5  Adjusted rate differences in tendon rupture with fluoroqui-
nolone exposure and concomitant oral corticosteroid exposure (per 
10,000 patients)
ADR adjusted rate difference, the additional number of expected 
events per 10,000 patients per year
Variable Any tendon Achilles tendon
ARD 95% CI ARD 95% CI
Fluoroquinolone exposure
Overall 2.9 2.2–3.7 2.1 1.6–2.7
Males 2.3 1.8–3.0 1.6 1.3–2.1
Females 3.1 2.4–4.0 2.1 1.6–2.7
Age < 60 years 1.4 1.0–1.8 1.2 0.9–1.6
Age ≥ 60 years 5.6 4.3–7.2 3.0 2.3–3.9
Fluoroquinolone plus oral 
corticosteroid exposure
Overall 10.9 8.3–14.0 4.9 3.7–6.2
Males 14.6 11.2–18.8 5.5 4.2–7.1
Females 7.9 6.0–10.1 3.9 3.0–5.0
Age < 60 years 6.0 4.6–7.7 2.1 1.6–2.7
Age ≥ 60 years 19.6 15.0–25.2 6.6 5.0–8.4
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and increases by ~ 6% with each day of current exposure. 
People with prior tendon rupture, co-morbidity, those with 
increasing BMI and those prescribed oral corticosteroids 
were at increased risk of tendon rupture, with a significant 
interaction detected between concomitant fluoroquinolone 
and oral corticosteroid therapy. This interaction has previ-
ously been reported but with variable precision, with an 
OR ranging from 9.1 to 43.2 [10, 16, 19]. Information on 
absolute risk is limited. Van der Linden et al. [16] report 
an excess absolute risk of Achilles tendon rupture of 3.2 
cases per 1000 patient years, although the method used to 
calculate this was not reported. In a related study, van der 
Linden et al. [17] report the incidence of Achilles tendon 
rupture in people aged 60 years and over as a population-
attributable risk, estimating that 2.2% of Achilles tendon 
rupture in patients aged 60–79 years and 6.3% in patients 
aged 80 years and over are attributable to fluoroquinolone 
exposure. This absolute risk estimate may be dependent 
on the prevalence of exposure in the population though. 
Although low, we found that absolute risk in this popula-
tion may be greater than that listed in the product infor-
mation for fluoroquinolones (which states less than 1 in 
10,000 patients). Although we estimate a population-
average adjusted rate difference (akin to excess risk) of 
~ 2.9 tendon ruptures per 10,000 person years, absolute 
risk was greater in certain subgroups, significantly vary-
ing by age, concomitant corticosteroid exposure and, to a 
lesser extent, gender. Lastly, statin therapy has previously 
been linked to tendon disorders using spontaneous reports 
and pharmacovigilance databases [30]. Our study found no 
significant increased risk with statin use, in keeping with 
three other recent observational studies [31–33].
Our study has strengths and limitations. We matched on 
general practice so that controls were more likely to have 
similar socio-economic deprivation status and health-care 
physician prescribing behavior, helping to reduce con-
founding by indication. Only small numbers of cases were 
included unmatched on general practice, with sensitivity 
analysis demonstrating this had negligible influence on the 
observed results. Despite adjustment for multiple confound-
ers, risk of residual unmeasured confounding remains pos-
sible, which may include channeling bias, although evaluat-
ing the risk of tendon rupture with co-amoxiclav exposure 
consistently showed no statistically significant association. 
Very few traumatic tendon ruptures were explicitly recorded 
and it is not possible to determine what proportion of other 
events may have been associated with trauma, if any. Anti-
biotic exposures were identified through prescriptions issued 
within general practice. Our study focuses on tendon rupture 
only and further investigation on the risk of tendinitis may 
be useful for clinical decision making. Similarly, we focus 
on fluoroquinolone as a class and risk associated with indi-
vidual fluoroquinolone products requires further evaluation.
Antibiotic stewardship aimed at reducing fluoroqui-
nolone exposure may prevent unnecessary harm but this 
may not be possible or appropriate for all patients. Despite 
the relatively large increase in risk associated with con-
comitant exposure to systemic fluoroquinolones and cor-
ticosteroids, relatively little attention is given to this inter-
action among clinical guideline recommendations. This 
may have implications for special patient groups such as 
in the management of asthma, chronic obstructive pulmo-
nary disease or bronchiectasis exacerbations, which may 
require concomitant use of both antibiotics and oral cor-
ticosteroids regimens, for example, and commonly have 
other risk factors such as co-morbidity [34–36].
This study was conducted to provide further informa-
tion to quantify the risk of tendon ruptures associated with 
fluoroquinolone antibiotics to support a review of safety 
information at the EMA PRAC in order to aid regulatory 
decision making for the use of fluoroquinolones across 
Europe. In this regard, tendon rupture is only one poten-
tial adverse effect of fluoroquinolone exposure, with other 
potential adverse effects associated with peripheral neu-
ropathy and aortic aneurysm having been reported [20, 
37–40].
In conclusion, the risk of tendon rupture associated with 
fluoroquinolone therapy appears to depend on timing, dose 
and concomitant exposure to corticosteroids, and affects 
elderly patients the greatest in absolute terms; patients and 
healthcare professionals should be informed of these risks.
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